In response to the public health emergency posed by the COVID-19 pandemic, National Health Service (NHS) England and NHS Improvement have established a rapid policy development process to aid clinicians in offering best care and advice to patients with high risk of coronavirus. This has led to awareness about ruxolitinib, which is found to be effective in treating acute graft versus host disease (GvHD) patients who have not responded to steroids. Ruxolitinib is a tablet that can be consumed at home, which eliminates the need for a patient to visit hospital frequently and reduce the risk of contracting COVID-19.
Companies in the acute graft versus host disease (GvHD) treatment market are increasing their output capacities and maintaining steady supply for ruxolitinib as an alternative treatment option, which is reducing the need to attend hospital unless adverse events occur.
These factors are anticipated to drive the acute graft versus host disease (GvHD) treatment market during the forecast period.
-treatment-market-infographic.jpg)
Clinically significant GvHD occurs frequently in spite of prophylaxis, which has led to the demand for corticosteroids as the mainstay of frontline therapy. However, in many cases, these drugs can have severe adverse effects and outcomes are dismal in patients who historically have had limited treatment options. Such findings are affecting the growth of the global acute graft versus host disease (GvHD) treatment market. Hence, companies in the acute graft versus host disease (GvHD) treatment market are boosting their R&D capabilities to successfully manufacture drugs that can be administered in a multicenter environment.
Steroid resistance has been found in GvHD patients. This condition is difficult to treat and associated with a high mortality rate. In order to overcome these issues, companies in the acute graft versus host disease (GvHD) treatment market are boosting their output capacities for Ruxolitinib. This tablet holds promising potential as a treatment option for patients with steroid-refractory aGvHD after allogeneic hematopoietic stem cell transplantation.
Ruxolitinib tablet works by blocking the action of enzymes known as Janus kinases (JAKs) that are involved in the production and growth of blood cells & immune function. By blocking JAKs, ruxolitinib reduces the abnormal production of blood cells, which helps to reduce the symptoms of GvHD. This tablet helps to address the side effects linked with the consumption of steroids.
The gastrointestinal damage is a leading cause of death in patients with acute GvHD. The clinical stage biopharmaceutical company VectivBio Holding AG is gaining cognizance about this condition and has received the FDA orphan drug designation for apraglutide, a next-generation, long-acting GLP-2 analog being developed for rare gastrointestinal (GI) diseases for the prevention of aGVHD. Companies in the acute graft versus host disease (GvHD) treatment market are gaining knowledge about such drug innovations and increasing their research capabilities.
Preclinical and clinical studies evaluating apraglutide & GLP-2 analogs in aGvHD indicate that apraglutide’s regenerative and anti-inflammatory effects on the GI tract may help to significantly reduce morbidity and mortality in patients suffering from intestinal GvHD.
-treatment-market-segmentation.jpg)
Analysts’ Viewpoint
The ruxolitinib tablet is helping to avoid the need for urgent hospitalization in high-risk patients during the ongoing COVID-19 outbreak. The acute graft versus host disease (GvHD) treatment market is slated to clock a favorable CAGR of 8.6% during the forecast period. However, the high prevalence of steroid resistance has been found in GvHD patients. Hence, companies in the acute graft versus host disease (GvHD) treatment market should boost their production for ruxolitinib, which helps to improve outcomes in patient with steroid-refractory aGvHD after the allogeneic hematopoietic stem cell transplantation. As such, the acute graft versus host disease (GvHD) treatment market is expected to reach US$ 634.3 Mn by 2031.
Acute graft versus host disease treatment market is expected to reach US$ 634.3 Mn by 2031
Acute graft versus host disease treatment market is slated to clock a favorable CAGR of 8.6% during 2021-2031
Acute graft versus host disease treatment market is driven by rise in focus on introducing novel effective therapeutics to address the unmet medical needs
North America accounted for a major share of the global acute graft versus host disease (GvHD) treatment market during the forecast period
Key players in the global acute graft versus host disease treatment market include Bristol-Myers Squibb, Novartis AG, Mesoblast Ltd., Equillium, Inc., Cynata Therapeutics Limited
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Graft Versus Host Disease (GvHD) Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definitions
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. COVID-19 Pandemics Impact on Industry (value chain and short / mid / long term impact)
5.2. Key Industry Events
5.3. Pipeline Analysis
5.4. Overview of Companies Offering stem cell treatment and/or Treg cell treatment for Acute Graft Versus Host Disease (GvHD)
5.5. Treatment and Management of Acute Graft Versus Host Disease (aGvHD)
6. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Corticosteroids
6.3.2. Immunosuppressive Agents
6.3.3. Biological Therapy
6.3.4. Kinase Inhibitors
6.3.5. Monoclonal Antibody
6.3.6. Mesenchymal Stem Cell (MSC)
6.3.7. Others
6.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class
7. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Topical
7.3.3. Intravenous
7.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration
8. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel
9. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Region
10. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
10.2.1. Corticosteroids
10.2.2. Immunosuppressive Agents
10.2.3. Biological Therapy
10.2.4. Kinase Inhibitor
10.2.5. Monoclonal Antibody
10.2.6. Mesenchymal Stem Cell (MSC)
10.2.7. Others
10.3. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
10.3.1. Oral
10.3.2. Topical
10.3.3. Intravenous
10.4. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Route of Administration
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
11.2.1. Corticosteroids
11.2.2. Immunosuppressive Agents
11.2.3. Biological Therapy
11.2.4. Kinase Inhibitors
11.2.5. Monoclonal Antibody
11.2.6. Mesenchymal Stem Cell (MSC)
11.2.7. Others
11.3. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
11.3.1. Oral
11.3.2. Topical
11.3.3. Intravenous
11.4. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Route of Administration
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Corticosteroids
12.2.2. Immunosuppressive Agents
12.2.3. Biological Therapy
12.2.4. Kinase Inhibitors
12.2.5. Monoclonal Antibody
12.2.6. Mesenchymal Stem Cell (MSC)
12.2.7. Others
12.3. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
12.3.1. Oral
12.3.2. Topical
12.3.3. Intravenous
12.4. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Route of Administration
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Corticosteroids
13.2.2. Immunosuppressive Agents
13.2.3. Biological Therapy
13.2.4. Kinase Inhibitors
13.2.5. Monoclonal Antibody
13.2.6. Mesenchymal Stem Cell (MSC)
13.2.7. Others
13.3. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
13.3.1. Oral
13.3.2. Topical
13.3.3. Intravenous
13.4. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Route of Administration
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Drug Class, 2017–2031
14.2.1. Corticosteroids
14.2.2. Immunosuppressive Agents
14.2.3. Biological Therapy
14.2.4. Kinase Inhibitors
14.2.5. Monoclonal Antibody
14.2.6. Mesenchymal Stem Cell (MSC)
14.2.7. Others
14.3. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Route of Administration, 2017–2031
14.3.1. Oral
14.3.2. Topical
14.3.3. Intravenous
14.4. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Route of Administration
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Ranking, by Company, 2020
15.3. Company Profiles
15.3.1. Bristol-Myers Squibb
15.3.1.1. Company Description
15.3.1.2. Business Overview
15.3.1.3. Strategic Overview
15.3.1.4. SWOT Analysis
15.3.2. Novartis AG
15.3.2.1. Company Description
15.3.2.2. Business Overview
15.3.2.3. Strategic Overview
15.3.2.4. SWOT Analysis
15.3.3. Mesoblast Ltd
15.3.3.1. Company Description
15.3.3.2. Business Overview
15.3.3.3. Strategic Overview
15.3.3.4. SWOT Analysis
15.3.4. Equillium, Inc.
15.3.4.1. Company Description
15.3.4.2. Strategic Overview
15.3.4.3. SWOT Analysis
15.3.5. Cynata Therapeutics Limited
15.3.5.1. Company Description
15.3.5.2. Business Overview
15.3.5.3. Strategic Overview
15.3.5.4. SWOT Analysis
15.3.6. MaaT Pharma
15.3.6.1. Company Description
15.3.6.2. Strategic Overview
15.3.6.3. SWOT Analysis
15.3.7. Incyte Corporation
15.3.7.1. Company Description
15.3.7.2. Business Overview
15.3.7.3. Strategic Overview
15.3.7.4. SWOT Analysis
15.3.8. Xenikos B.V.
15.3.8.1. Company Description
15.3.8.2. Strategic Overview
15.3.8.3. SWOT Analysis
15.3.9. Merck & Co. (OncoImmune, Inc.)
15.3.9.1. Company Description
15.3.9.2. Business Overview
15.3.9.3. Strategic Overview
15.3.9.4. SWOT Analysis
15.3.10. medac GmbH
15.3.10.1. Company Description
15.3.10.2. SWOT Analysis
15.3.11. CSL Limited
15.3.11.1. Company Description
15.3.11.2. Business Overview
15.3.11.3. SWOT Analysis
List of Tables
Table 01: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031 (1/2)
Table 02: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031 (2/2)
Table 03: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 04: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 05: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 08: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 09: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 10: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 12: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 13: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 14: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 15: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 16: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 17: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 18: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 19: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 20: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 21: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 22: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 24: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 25: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Drug Class, 2020
Figure 03: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Route of Administration, 2020
Figure 04: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Distribution Channel, 2020
Figure 05: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share, by Region, 2020
Figure 06: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
Figure 07: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031
Figure 08: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Corticosteroids, 2017–2031
Figure 09: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Immunosuppressive Agents, 2017–2031
Figure 10: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Biological Therapy, 2017–2031
Figure 11: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Kinase Inhibitors, 2017–2031
Figure 12: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Monoclonal Antibody, 2017–2031
Figure 13: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Mesenchymal Stem Cell, 2017–2031
Figure 14: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Others, 2017–2031
Figure 15: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 16: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 17: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Oral, 2017–2031
Figure 18: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Topical, 2017–2031
Figure 19: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Intravenous, 2017–2031
Figure 20: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 21: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 22: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 23: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 24: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031
Figure 25: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Region, 2020 and 2031
Figure 26: Global Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Region, 2021–2031
Figure 27: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 28: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country, 2020 and 2031
Figure 29: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country, 2021–2031
Figure 30: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
Figure 31: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031
Figure 32: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 33: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 34: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 35: North America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 36: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 37: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 38: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 39: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
Figure 40: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031
Figure 41: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 42: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 43: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 44: Europe Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 45: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 46: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 47: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 48: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
Figure 49: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031
Figure 50: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 51: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 52: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 53: Asia Pacific Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 54: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 55: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 56: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 57: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
Figure 58: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031
Figure 59: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 60: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 61: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 62: Latin America Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 63: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value (US$ Mn) Forecast, 2017–2031
Figure 64: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 65: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 66: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Drug Class, 2020 and 2031
Figure 67: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Drug Class, 2021–2031
Figure 68: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 69: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 70: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 71: Middle East & Africa Acute Graft Versus Host Disease (GvHD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 72: Market Position Analysis, by Tier and Size of Company
Figure 73: Bristol-Myers Squibb Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 –2020
Figure 74: Bristol-Myers Squibb Breakdown of Net Sales (%), by Region/Country, 2020
Figure 75: Bristol-Myers Squibb R&D Expenses (US$ Mn) 2017–2020
Figure 76: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 77: Novartis AG Breakdown of Net Sales (%), by Region/Country, 2020
Figure 78: Novartis AG Revenue Breakdown of Net Sales (%), by Business Segment, 2020
Figure 79: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 80: Mesoblast Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 81: Mesoblast Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 82: Cynata Therapeutics Limited Business Overview
Figure 83: Incyte Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 84: Incyte Corporation JAKAFI Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 85: Incyte Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 86: Merck & Co. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 87: Merck & Co. Breakdown of Net Sales (%), by Region/Country, 2020
Figure 88: Merck & Co. Revenue Breakdown of Net Sales (%), by Business Segment, 2020
Figure 89: Merck & Co. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 90: CSL Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020
Figure 91: CSL Limited Breakdown of Net Sales (%), by Region/Country, 2020
Figure 92: CSL Limited Revenue Breakdown of Net Sales (%), by Business Segment, 2020
Figure 93: CSL Limited R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Acute Graft Versus Host Disease [GvHD] Treatment Market Insights, 2021-2031
